Organisation paid for research Program year 2023 Source: CMS Open Payments

Aspen Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$538,690

60 payments

Through program year 2023, Aspen Clinical Research is reported as receiving $538,690 in research payments, across 60 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $78,913 5
2022 Research $20,261 5
2021 Research $21,280 1
2020 Research $166,730 19
2019 Research $251,506 30

Breakdown

Who paid Research payments · program years 2019–2023
  1. Supernus Pharmaceuticals, Inc. $303,690 40 payments
  2. AstraZeneca Pharmaceuticals LP $99,018 4 payments
  3. Pfizer Inc. $43,099 7 payments
  4. H. Lundbeck A S $40,891 2 payments
  5. AstraZeneca UK Limited $36,484 2 payments
  6. Novartis Pharmaceuticals Corporation $13,410 2 payments
  7. Janssen Research & Development, LLC $1,598 2 payments
  8. Merck Sharp & Dohme Corporation $500 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $135,502 6 payments
  2. Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects With Attention Deficithyperactivity Disorder $85,121 11 payments
  3. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $77,084 10 payments
  4. Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder $58,852 7 payments
  5. A Phase 1 First in Human Randomized Double Blind Sponsor Open Placebocontrolled Single and Multiple Dose Escalation Parallel Group Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of PF 07242813 in Healthy Participants and Participants With Atopic Dermatitis $43,099 7 payments
  6. Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD $39,560 1 payment
  7. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficithyperactivity Disorder Adhd in Conjunction With Standard Adhd Treatment $31,242 4 payments
  8. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) in Conjunction With Standard Adhd Treatment $18,697 1 payment
  9. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficithyperactivity Disorder Adhd $16,382 1 payment
  10. Assessment of Efficacy and Safety of Spn-810 for the Treatment of Impulsive Aggression Ia in Adolescent Subjects With Attention Deficithyperactivity Disorder Adhd in Conjunction With Standard Adhd Treatment $14,068 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record